Commentary: Emerging role of GIP and related gut hormones in fertility and PCSOS

Dawood Khan, R Charlotte Moffett*

SAAD Centre for Pharmacy and Diabetes, Ulster University, Coleraine, Northern Ireland, UK

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with infertility which affects one in ten women in the United Kingdom. Women with PCOS are typified by insulin resistance, gestational diabetes and obesity. Therefore, a close association between reproductive function and nutrition is postulated. However, regulatory pathways common to energy and reproductive function have received little attention. Recent research shows rapid amelioration of infertility, PCOS and type 2 diabetes following Roux-en-Y bariatric surgery (RYGB). This occurs prior to weight loss suggesting involvement of gut derived factors. Therefore, gut hormones emerge as key players in the regulation of both energy homeostasis and possibly reproductive function. Alteration of gut peptide levels including GLP-1, GIP, PYY, ghrelin, NPY and neurotensin post-bariatric surgery suggest a plausible mechanism behind beneficial effects of RYGB. Furthermore, expression of gut peptide receptors within the reproductive axis strengthen the idea of involvement of these hormones in the remission of fertility post-surgery. The present commentary discusses the role of these important gut peptides and their receptors in the regulation of female reproductive system in the light of a recent article published by our laboratory. Understanding the functional relationship between the gut and reproductive axis will help us to identify novel and less invasive alternatives to bariatric surgeries for reproductive and related metabolic disorders.

Substantial evidence reveals a correlation between female infertility and type 2 diabetes (T2D). Major cause of female infertility associated with metabolic syndrome such as T2D is polycystic ovarian syndrome (PCOS). PCOS, a reproductive and metabolic disorder affecting 5–10% of women in their fertile years, which induces symptoms including reproductive abnormalities, altered androgen levels, hyperinsulinaemia together with insulin resistance and risk of gestational diabetes. Roux-en-Y bariatric surgery (RYGB) is a gold standard treatment for long-term weight loss in morbidly obese people. In addition to weight loss, RYGB promotes blood glucose control, corrects menstrual disturbances and ameliorates PCOS thereby increasing fertility. Interestingly, alteration of gut hormones such as gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) has been shown to play key roles in the remission of obesity and diabetes post bariatric surgery. However, the functional connection between gut hormones and reproductive dysfunction has received little attention.

In the recent work published by our laboratory, Moffett and Naughton (2020) highlight metabolic benefits of RYGB in the treatment of PCOS and possible mechanisms through which gut hormones may be involved in female reproductive function. In recent
years, gastric bypass surgeries have become an effective tool to treat obesity and improve related comorbidities such as insulin resistance, cancer, reproductive dysfunction and cardiovascular disorders are observed post-surgery. However, high-cost, invasiveness and irreversibility of the procedure prevents RYGB becoming a more common and popular mode of treatment. Therefore, unravelling the mechanism(s) behind multifaceted benefits of bariatric surgeries is vital to provide less invasive and cost-effective alternatives targeting tissue-specific impacts.

Interestingly, even before weight loss is achieved, RYGB confers other disproportionate health benefits\(^9\). Although the exact mechanism is unclear, the Moffett & Naughton (2020)\(^8\) article gives important clues. Firstly, increased secretion and circulation of key gut peptides including GLP-1, PYY and oxyntomodulin is observed which may be a vital driving factor post RYGB\(^11,12\). These hormones act as agonists for GLP-1R, NPYRs and glucagon receptors which modulate various pathways regulating satiety, beta-cell function and fat metabolism. Secondly, following RYGB, gut hormones including GIP and ghrelin are markedly decreased in circulation. Although there are debates surrounding serum GIP levels post RYGB, role of GIP in energy storage is well studied\(^13\). Similarly, decreased levels of ghrelin post RYGB may explain reduced hunger as it stimulates appetite in short-term and in long-term plays a key role in fat storage\(^14\). In addition to the afore mentioned peptides, neurotensin is another gut hormone that has received relatively little attention with regards to bariatric surgeries. Recent clinical studies show elevated levels of pro-neurotensin postprandially after RYGB suggesting relevance of gut peptides other than incretins mediating beneficial effects of RYGB\(^15,16,17\).

An important question raised by the article is "What happens to PCOS after RYGB surgery and are same mechanisms revolving around gut hormones involved? Recent studies show significant resolution of PCOS post bariatric surgery in 96 % of affected women\(^5\). Studies involving 2130 females with mean BMI of 48.1 kg/m\(^2\) significantly reduced incidence of PCOS from 45.6% to 6.8% at 12-month post-operative follow up\(^19\). This included positives effects on hirsutism and menstrual irregularities which are key clinical symptomatology in PCOS\(^18\). In 1960s, close association between critical body weight and female reproductive capacity was postulated suggesting adaptive response to poor nutrition\(^19\).

Although not being part of the hypothalamic-pituitary-gonadal reproductive axis, gut peptides may affect endometrial and other related functions. These gut peptides interfere with the regulation of reproductive systems at various levels based on sex, species or stage of puberty\(^19\). One such peptide is GLP-1. GLP-1, mainly secreted from intestinal L-cells is evidently shown to be involved in modulation of hypothalamic gonadotropin-releasing hormone (GnRH) neurons\(^20,21,22,23\) (Figure1). Interestingly, an increased level of plasma GLP-1 is also observed during pro-oestrous phase in time-related manner\(^24\). Furthermore, expression of GLP-1 receptor mRNA in the hypothalamus peaked during pro-oestrous stage suggesting a crosstalk between GLP-1 and its receptor\(^22\). Studies with GLP-1R knockout mice revealed significantly decreased number of ovarian follicles\(^25\). Data from these studies suggest GLP-1 as a key player in fertility.

Another important incretin hormone highlighted in the review article by Moffett & Naughton (2020)\(^8\) is GIP. GIP, produced by intestinal K cells, increases glucose uptake and inhibition of lipolysis in adipocytes after inhibition of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme which regulates cortisol\(^26\). Furthermore, studies show decreased hepatic 11β-HSD1 activity in obese women with PCOS and expression of GIP receptors in ovaries and testes\(^27\). Women with PCOS also show increase in total GIP concentrations\(^28\). Taken together, these data propose unsuspected role of GIP as an important contributing factor in reproductive function. Evidence suggest that modulation of both GIPR and GLP-1R significantly suppresses progesterone synthesis in the presence of FSH and expression of many progesterogenic factors and enzymes\(^29\) (Figure1). Further studies exploring synergistic effects of GLP-1 and GIP using dual receptor agonist/antagonist will be necessary to fully understand the significance of GLP-1R and GIPR signalling for activation of various pathways involved in female fertility.

PYY, mainly secreted from intestinal L-cells together with GLP-1 regulates feeding and beta cell function inhibiting insulin secretion\(^30\). Although, its role in reproductive axis is not well studied, it is important to note that PYY administration inhibits GnRH secretion in male rats (Figure1) and delayed the estradiol-induced LH surge in ovariectomized ewes\(^11,13\). Neuropeptide Y, another orexigenic Y receptor agonist, exhibits decreased plasma levels in overweight and obese patients with PCOS\(^31\). Interestingly, NPY response to ghrelin in obese women with PCOS was significantly reduced in plasma as shown by Romualdi et al. in 2008\(^34\). As insulin inhibits hypothalamic NPY gene expression, variation in plasma NPY levels in PCOS may be attributed to insulin action\(^33\). Since NPY receptor subtypes are expressed in adrenal cortex, ovaries and pituitary\(^32,36\). It is imperative to clarify the exact role of PYY and NPY on the reproductive axis in relation to PCOS associated with obesity.

Ghrelin is a 28 amino acid peptide mainly secreted by stomach\(^37\). Ghrelin regulates glucose metabolism, food intake, motility of gastrointestinal tract and controls reproductive functions binding to growth hormone receptors. Women with obesity and PCOS showed
significant reduction in plasma ghrelin levels\textsuperscript{38}. Expression of ghrelin and its receptor in reproductive organs including endometrium and testis, phase-dependant ghrelin mRNA fluctuation in rat ovaries, and ghrelin mediated control of prolactin secretion in both rats and humans suggests possible role in the reproductive function\textsuperscript{29,40}.

Neurotensin, a 13 amino acids neuropeptide is found in the central nervous system, small intestine and stomach\textsuperscript{41}. It functions as a modulator of the dopaminergic system\textsuperscript{53}. Neurotensin immunoreactivity is reported in rodent uterus, endometrium epithelium and oviduct with neurotensin suggested as a key factor in facilitating sperm function during fertilization\textsuperscript{44}(Figure1). Studies are required to determine if neurotensin and its receptors mediate signalling pathways in reproduction. Figure1 below summarizes key gut hormones, predominant site of secretion, circulatory changes in RYGB and reproductive actions.

Although obesity and PCOS frequently coexist in female adult and adolescent population, clinical studies covering the three conditions (morbid obesity, PCOS, and RYGB) simultaneously are scarcely available\textsuperscript{44,45,46}. Previous study showed significant weight loss post bariatric surgery leading to complete resolution of PCOS including improvements in menstrual cycle, hirsutism and insulin resistance in 17 women\textsuperscript{47}. Study by Turkmen and colleagues showed improvement in eating behaviour and clinical symptoms of PCOS post-RYGB in 9 female patients\textsuperscript{48}. Similarly, all female participants with infertility and PCOS (N=6; N=5) were able to conceive post-RYGB\textsuperscript{49,50}. However, one attribute common to the afore mentioned studies is small sample size limiting the interpretation of data. Although preclinical studies highlight the efficacy of RYGB in the treatment of PCOS associated with obesity, more extensive assessment is required to establish their translational potential to clinical settings. Nevertheless, studies with substantial sample size and randomized controls focusing on altered incretin and androgens levels post-RYGB in obese females may offer better understanding in this relatively new area of research.

In summary, the review by Moffett and Naughton (2020)\textsuperscript{8} opens up a fascinating field of research by highlighting the role of altered gut hormonal milieu post RYGB in ameliorating PCOS and increasing female fertility. Clearly, advantages of incretins and other related gut peptides go far beyond managing T2D and their full potential remains to be proven that may benefit patients with reproductive dysfunction. Their review should be viewed, not as an endorsement of use of incretin-based therapies in the treatment of obesity-related PCOS, but rather, as an invitation for further studies to elucidate the mechanism linking modulation of gut hormone receptors in reproductive and hypothalamic-pituitary-adrenal axis. This could reveal novel therapies for reproductive dysfunction associated with metabolic disturbances.

Acknowledgements

RCM and DK are supported by an RD Lawrence Research Fellowship awarded by Diabetes UK to RCM.

---

**Figure 1:** Summary of major gut peptides, their predominant secretion sites, adaptation post-RYGB and associated reproductive functions. Gut hormones act to exert a variety of physiological roles mainly associated with energy and glucose metabolism. The figure summarizes the overall effect of gut hormones included in the commentary on the reproductive axis established by currently available literature.

---

**Table:**

- **Gut peptides**
  - GIP
  - GLP-1
  - Ghrelin
  - PYY
  - NPY
  - Neurotensin

- **Predominant site of secretion**
  - GIP: K cells in the intestinal epithelium
  - GLP-1: Intestinal L-cells
  - Ghrelin: Endocrine cells in the stomach, also released by small intestine, pancreas and brain
  - PYY: Intestinal L-cells
  - NPY: Released from sympathetic nerve endings and pancreatic cells
  - Neurotensin: Enteroadrenocorticotropin (ACTH) cells and in the nerves of hypotalamic plexus

- **Altered levels post RYGB**
  - GIP: Shown to either increase, unchanged or decrease due to variation in surgical techniques
  - GLP-1: Large increase in circulating GLP-1 postprandially
  - Ghrelin: Circulating ghrelin levels were significantly reduced post-RYGB
  - PYY: Both fasting and postprandial PYY levels increase significantly post-RYGB
  - NPY: No significant changes in NPY levels post RYGB
  - Neurotensin: Elevated levels of pre-neurotensin postprandially after RYGB

- **Reproductive actions**
  - GIP: Increases LH and FSH secretion in vitro, decreases FSH in vivo (rat) and manipulation with both GIP and GLP-1 suppresses progesterone synthesis in the presence of FSH
  - GLP-1: Stimulates GnRH secretion, increases hypothalamic kisspeptin, increases the preovulatory luteinizing hormone (LH) surge and increases LH-independent testosterone pulse frequency in healthy men
  - Ghrelin: Decrease LH responsiveness to LHRH in vitro, suppress LH secretion in vivo, controls prolactin secretion and inhibits testosterone synthesis in rats
  - PYY: 1 GnRH release in fasted but 1 GnRH in fed adult rat, PYY[3-36] stimulates rat pituitary production of LH and FSH and 1 gonadotrophin in prepubertal male rats
  - NPY: No significant changes in NPY levels post RYGB
  - Neurotensin: Enhances sperm capacitation and acrosomes reaction in mice and cattle, NTR1 expressed in mouse sperm

---
Conflict of interest
No potential conflict of interests relevant to this article were reported.

References


